{"nct_id":"NCT06898957","title":"Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2025-05-16","start_date_type":"ACTUAL","primary_completion_date":"2031-05-21","primary_completion_date_type":"ESTIMATED","completion_date":"2031-05-21","completion_date_type":"ESTIMATED","phases":["PHASE1"],"tickers":["AMGN"]}